7ZK-27805-99487
4 vaccinations
3 coded responses
44 check-ins
1 free-text entry
2 call cases
- Sex
- Male
- Age at first dose
- 0-4
- ZIP prefix
- 273 / NC
- Registered
- 2022-06-25
- Relationship
- Child or adolescent in my care
- Guardian
- QX5-94880-48584
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-06-23
Dose 1 — Pfizer-BioNTech
-
2022-06-25
Registered in v-safe
- 2022-06-25
- 2022-06-26
- 2022-06-27
-
2022-06-28
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Fair · Fever · None · Be unable to work or attend schoolUnder 3 check-in
-
2022-06-29
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Good · None · Be unable to work or attend schoolUnder 3 check-in
- 2022-06-30
- 2022-07-07
-
2022-07-14
Dose 2 — Pfizer-BioNTech
- 2022-07-14
- 2022-07-15
- 2022-07-16
- 2022-07-17
- 2022-07-18
- 2022-07-19
- 2022-07-20
- 2022-07-21
- 2022-07-28
- 2022-08-04
- 2022-08-11
- 2022-08-18
- 2022-08-27
-
2022-09-08
Dose 3 — Pfizer-BioNTech
- 2022-09-09
- 2022-09-10
- 2022-09-11
- 2022-09-12
- 2022-09-14
-
2022-09-17
Health check-in — day 7, dose 3, under 3Feeling: Good · Fever · None · Be unable to work or attend schoolUnder 3 check-in
- 2022-09-22
- 2022-09-29
-
2022-10-06
Survey response — day 28, dose 3, under 3MedDRA: Conjunctivitis — Feeling: Good · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Pink eye infectionMedDRA releases: 2024-11 · check-in free text available
-
2022-10-06
Report sent to call center — day 28, dose 3, under 3Be unable to work or attend school · Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-10-07
- 2022-10-13
-
2022-10-19
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2022-10-20
- 2022-12-08
- 2023-03-09
-
2023-05-17
Dose 4 — Pfizer-BioNTech
- 2023-05-19
- 2023-05-20
-
2023-05-21
Survey response — days 1–6 daily, dose 4, under 3MedDRA: Cough, Rhinorrhoea — Feeling: Fair · FeverMedDRA releases: 2024-11
- 2023-05-22
-
2023-05-23
Survey response — days 1–6 daily, dose 4, under 3MedDRA: Cough — Feeling: Fair · Fever · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11
-
2023-05-23
Call case (no matching report) — SuccessfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2023-05-24
- 2023-05-24
-
2023-05-24
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2023-05-31
- 2023-06-07
- 2023-06-14
- 2023-06-21
- 2023-06-28
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-06-23 | Pfizer-BioNTech | No |
| 2 | 2022-07-14 | Pfizer-BioNTech | No |
| 3 | 2022-09-08 | Pfizer-BioNTech | No |
| 4 | 2023-05-17 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 successful
Free text
Release 12 (Under 3) — day 28, dose 3, under 3
Symptoms: Pink eye infection
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Conjunctivitis | · | · | ✓ |
| SRO | Cough | · | · | ✓ |
| SRO | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release